Jolanda Howe, Senior Vice President and Global Controller at Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), executed a transaction on July 1, 2026, disposing of 2,721 shares of the company's common stock. The total value of the sale reached $326,520, calculated using a per-share price of $120.0. This divestment occurred while the equity was trading in close proximity to its 52-week high of $125.75, a level achieved after the stock recorded a substantial 156% gain over the preceding twelve months. Independent analysis from InvestingPro indicates that the current valuation of MIRM appears elevated when measured against its established Fair Value metrics.
The transaction was structured in accordance with a Rule 10b5-1 trading plan, which Howe formally adopted on March 18, 2026. Following this specific disposition, Howe maintains a direct ownership position of 3,114 shares of Mirum Pharmaceuticals common stock.
Concurrent with the executive sale, Mirum Pharmaceuticals has announced the successful pricing of $600 million in convertible senior notes maturing in 2032. These debt instruments carry a 0.00% interest rate and are scheduled to settle on May 15. The offering includes an option for initial purchasers to acquire an additional $90 million in notes, providing potential upside for the financing round.
Analyst coverage of the company has seen notable activity. Wolfe Research initiated coverage on Mirum Pharmaceuticals with an outperform rating and assigned a $145 price target. The firm's thesis centers on expectations that Livmarli will reach peak worldwide sales of approximately $940 million. Meanwhile, Citizens raised its price target on Mirum shares to $146 from $140, maintaining a Market Outperform rating. This adjustment followed Mirum's acquisition of zilurgisertib from Incyte. The drug represents a identified $200 million opportunity for Mirum, acquired for $16 million upfront with potential milestone payments attached. H.C. Wainwright reiterated a Buy rating with a $185 price target, referencing interim data from the ongoing PROGRESS study evaluating zilurgisertib. Citizens also reiterated a Market Outperform rating with a $140 price target, highlighting upcoming clinical readouts expected over the next two years.
These corporate actions and analyst revisions reflect ongoing strategic initiatives within the pharmaceutical sector, impacting equity markets through capital structure adjustments and valuation reassessments. The convertible note issuance introduces debt dynamics into the capital structure, while the acquisition of zilurgisertib signals expansion in the specialty chemical and pharmaceutical pipeline. Market participants are monitoring the execution of these strategies against the backdrop of the stock's recent performance and fair value assessments.